WASHINGTON — Oregon is gearing up to ask the Biden administration if its Medicaid program can avoid paying for drugs approved through a fast-track approval pathway — like Biogen’s pricey, controversial new Alzheimer’s drug, Aduhelm.
Oregon announced this month it is planning to formally submit a request to the administration to let its state out of a law that requires Medicaid programs to cover nearly all Food and Drug Administration-approved drugs.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
